Related coverage linked through entity extraction aliases.
Jul 17, 2026
New CAR T-cell data show 100% MRD negativity in high-risk smoldering multiple myeloma, a novel CAR T approach for AML, and a new T-cell pathway, while a case report warns of a rare therapy-related complication.
Aug 05, 2026
Insilico Medicine named ISM9528 as its 31st AI-driven preclinical pain candidate, published a target discovery study for a rare sinonasal cancer, and advanced partnerships with MSK and Takeda. The company is also presenting oncology programs at AACR 2026.
Jun 09, 2026
BostonGene announced a strategic collaboration with Daiichi Sankyo to integrate AI-driven analytics into an ADC development program. The company also revealed six abstracts will be presented at the EHA 2026 Congress in Stockholm. The research showcases integrated multiomics and predictive modeling for blood cancer treatment optimization.
Feb 27, 2026
A multi-institutional study found that pairing an investigational immunotherapy with hormone therapy before surgery reduced regulatory T cells in prostate tumors and improved cancer-free outcomes in high-risk patients.
Feb 19, 2026
Zsofia K. Stadler, MD, has been appointed as the next Editor-in-Chief of JCO Precision Oncology, effective July 1, 2026. She is an Attending Physician and Clinic Director at Memorial Sloan Kettering Cancer Center.
Feb 18, 2026
Insilico Medicine and Memorial Sloan Kettering Cancer Center have entered a collaborative research agreement to discover new therapeutic targets for gastroesophageal malignancies using AI-powered platforms and extensive multi-omic clinical datasets.
